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Recent findings on Antibiotic Resistance (AR) have brought renewed attention to the compar-
ison of data on AR from human and animal sectors. This is however a major challenge since
the data is not harmonized. This study performs a comparative analysis of data on resistance
combinations in Escherichia coli (E. coli) from different routine surveillance and monitoring
systems for human and different animal populations in Germany. Data on E. coli isolates
were collected between 2014 and 2017 from human clinical isolates, non-clinical animal iso-
lates from food-producing animals and food, and clinical animal isolates from food-producing
and companion animals from national routine surveillance and monitoring for AR in Germany.
Sixteen possible resistance combinations to four antibiotics—ampicillin, cefotaxime, cipro-
floxacin and gentamicin–for these populations were used for hierarchical clustering (Euclid-
ian and average distance). All analyses were performed with the software R 3.5.1 (Rstudio
1.1.442). Data of 333,496 E. coli isolates and forty-one different human and animal popula-
tions were included in the cluster analysis. Three main clusters were detected. Within these
three clusters, all human populations (intensive care unit (ICU), general ward and outpatient
care) showed similar relative frequencies of the resistance combinations and clustered
together. They demonstrated similarities with clinical isolates from different animal popula-
tions and most isolates from pigs from both non-clinical and clinical isolates. Isolates from
healthy poultry demonstrated similarities in relative frequencies of resistance combinations
and clustered together. However, they clustered separately from the human isolates. All iso-
lates from different animal populations with low relative frequencies of resistance combina-
tions clustered together. They also clustered separately from the human populations. Cluster
analysis has been able to demonstrate the linkage among human isolates and isolates from
various animal populations based on the resistance combinations. Further analyses based
on these findings might support a better one-health approach for AR in Germany.
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Introduction
Antibiotic resistance (AR) poses a global threat to humans, animals, and the environment [1].
AR in humans and different animal populations has increased in recent years. As noted in a
recent report [2], European countries have dealt with 670,000 human infections with resistant
bacteria in the year 2015. Third-generation cephalosphorin-resistant Escherichia coli (E. coli)
were the major cause with 290,000 infections. In animals, E. coli has also been studied intensively
in recent years since Extended-Spectrum-Beta-Lactamase/AmpC producing E. coli (ESBL/
AmpC E. coli) have been detected in food-producing animals [3, 4]. E. coli have, however, not
only been seen as very important pathogenic bacteria in humans and animals, but also as indica-
tor bacteria or commensal bacteria in animals that may play a specific role in the transmission of
AR genes from animals to humans [5, 6]. In order to tackle the increase in AR coming from
numerous sectors, a multi-disciplinary approach is necessary, as humans, animals and the envi-
ronment share similar resistance genes [7–12]. A “One Health” approach combines human, ani-
mal and environmental sectors in order to study, for example, transmission within and between
the different reservoirs. “One Health”-based initiatives have been launched on national, Euro-
pean and global levels to act on the spread of AR [13–17]. In Germany, the National Action Plan
on Antimicrobial Resistance (DART 2020, [18]) prioritizes adaption of this approach both
nationally and internationally. One major challenge in adapting the “One Health” approach in
Germany is the harmonization of data coming from various surveillance and monitoring systems
on AR. First, in concordance with DART 2020, this study addresses the comparison of the vari-
ous surveillance and monitoring systems on AR in human and veterinary medicine in Germany.
Second, we describe resistance combinations in each population using phenotypic AR-data of
non-clinical E. coli isolates from various food-producing animal populations including foods,
clinical E. coli isolates from food-producing and companion animal populations and clinical E.
coli isolates from different human populations collected through these surveillance and monitor-
ing systems. E. coli is used as a model organism because of its prevalence in animals and humans,
as well as the availability of respective data in Germany. In this study, non-clinical E. coli data
from different food-producing animal populations and food defined the commensal E. coli.
Finally, cluster analysis based on the relative frequencies of resistance combinations was used to
study similarities in resistance combinations of E. coli isolates from the investigated populations.
Materials and methods
Ethic statements
For human datasets, this study has solely included anonymised routine surveillance data. Ethi-
cal approval for analysis of such surveillance data is not required according to the Medical
Association’s professional code of conduct. Data on antimicrobial resistance of E. coli from
animals and food were collected in the framework of national monitoring projects and have
been published in aggregated form in the National reports as provided in the reference list.
The data basis of this analysis is presented in S4 Table.
Surveillance and monitoring of Antibiotic Resistance (AR) in Germany
Antibiotika-Resistenz-Surveillance (ARS) is the German national surveillance system for AR in
humans. It is coordinated by the Robert Koch Institute (RKI) since 2007. The system collects
routine laboratory data on AR in different bacterial pathogens that originate from clinical sam-
ples of patients in health care facilities (in- and outpatient care). It stores information on
demographics (e.g. age and gender of the patients), type and region of health care facility as
well type of hospital ward. Aggregated ARS datasets are sent to the European Antimicrobial
PLOS ONE Cluster analysis of Escherichia coli from different human and animal populations in Germany
PLOS ONE | https://doi.org/10.1371/journal.pone.0244413 January 20, 2021 2 / 19
Competing interests: The authors have declared
that no competing interests exist.
Resistance Surveillance Network (EARS-Net) in the European Centre of Disease Prevention
and Control (ECDC) and published annually. The participation of the laboratories in ARS is
voluntary [19]. Seventeen commercial diagnostic laboratories covering 187 hospitals and 3,436
general practices have participated continuously in ARS from the year 2014 to 2017 (Status:
May 2020). Antimicrobial susceptibility testing (AST) is conducted in the laboratories with
routine diagnostic procedures, such as automated broth-microdilution (ISO standard 20776–
1) [20] or agar disk diffusion [21]. Results are presented as susceptible (S), intermediate (I) and
resistant (R) (SIR) based on internationally harmonized evaluation criteria such as clinical
breakpoints provided by the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) and the Clinical Laboratory Standards Institute (CLSI).
Zoonosis-Monitoring (ZoMo) is the German monitoring system for AR in healthy food pro-
ducing animals and food. It is a collaboration between federal institutions (German Federal
Institute for Risk Assessment (BfR) and Federal Office of Consumer Protection and Food
Safety (BVL)), regional veterinary and food safety authorities and regional public laboratories.
Zoonosis-Monitoring has been implemented as national regulation according to Directive
2003/99/EC [22]. Details on mandatory bacteria-commodity combinations, antimicrobials
used in the testing, laboratory methods and evaluation criteria for the determined minimum
inhibitory concentrations (MIC) are fixed in Commission Implementing Decision (CID)
2013/652/EU [23]. In Germany, the federal states’ food safety authorities annually decide on a
sampling plan. They collect representative samples at different levels (farm, slaughter, retail) of
different food chains according to this sampling plan. Regional laboratories run by the federal
states isolate the bacteria from the samples and submit them to the National Reference Labora-
tory for Antimicrobial Resistance (NRL-AR). AST at the NRL-AR is done according to CID
2013/652/EU using broth-microdilution. For E. coli there is a fixed panel of 14 antibiotics used
in the testing (S1 Table). The MIC values are interpreted using Epidemiological Cut-Off
(ECOFF) values published by EUCAST and laid down in the CID. Results are reported to the
European Food Safety Authority (EFSA) and included in the annual “European Union sum-
mary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, ani-
mals and food” [6]. At the national level they are reported annually by the BVL [24–27].
The German Resistance Monitoring (GERM-Vet) on AR in animal pathogens is coordinated
and conducted by the BVL. Based on §77 [3] of the German Medicinal Products Act (AMG),
the BVL must report these data to the Federal Ministry of Food and Agriculture (BMEL) annu-
ally. Thirty-two participating public, private, and university laboratories submit voluntarily
bacterial pathogens from diseased animals based on an annual sampling plan for different ani-
mal populations and indications. This annual sampling plan is established together with par-
ticipating laboratories based on the experience from the previous years. Background
information on the animals that has been sampled (e.g. age, disease) is also stored in the sys-
tem. A customized BVL fixed panel of 24 antibiotics is used for AST in E. coli using broth
microdilution (S1 Table). MIC values with CLSI breakpoints for animal pathogens are rou-
tinely reported [28–30]. Table 1 summarizes the comparison between the three German sur-
veillance and monitoring systems.
Description of data and study design
We included E. coli data available in ARS, ZoMo and GERM-Vet from January 2014 to December
2017. From ARS we took only data from laboratories and health care facilities in Germany, which
participated in the system continuously from January 2014 to December 2017. The first isolate
per patient per type of clinical specimen per year was used for the analysis. Screening samples,
duplicate isolates (same type of clinical specimen from the same patient) and isolates with
PLOS ONE Cluster analysis of Escherichia coli from different human and animal populations in Germany
PLOS ONE | https://doi.org/10.1371/journal.pone.0244413 January 20, 2021 3 / 19
incomplete information were excluded. All used types of specimen are listed in Tables 2 and S3.
This study focused on qualitative interpretation of AST (SIR) according to EUCAST clinical
breakpoints. Further, ARS-data were classified by type of health care facility, i.e. human isolates
from intensive care units (ICU), general wards and from outpatient care. We included all E. coli
isolates from the annual sampling plans in ZoMo between 2014 and 2017. A summary of these
data has been previously published in annual national reports [24–27]. ZoMo data include food-
producing animals’ isolates from farms, slaughterhouses and from food at retail from all German
federal states (Table 2). Distribution of the samples across the federal states was proportionate to
the number of animals of the targeted animal population in the federal state for samples taken on
farms. For slaughterhouse samples, the distribution was proportionate to the slaughter capacity
within the federal state for the targeted animal population. Numbers of samples at retail were
based on the distribution of the human population. All materials are listed in Table 2.
The GERM-Vet study year lasts from April to March from each observation year. In this
study we included all E. coli-isolates, which had been collected from January 2014 to December
2017 (study years 2013 to 2017). A summary of the data has been published previously in
annual reports [28–30]. The isolates originated from diseased animals, which had not been
treated with antibiotics in the month prior to sampling. All materials along with the informa-
tion on diseases are listed in Table 2.
Four antibiotics were selected for the cluster analysis: ampicillin (AMP), cefotaxime (CTX),
ciprofloxacin (CIP) and gentamicin (GEN). They are included in the test panels of ZoMo and
GERM-Vet and likewise frequently tested in the medical laboratories reporting to ARS. Other
relevant antibiotics for E. coli such as colistin, carbapenems, co-trimoxazol, tetracycline could
not be included in this study because of the limited data available in the different systems. This
will be further explained in the discussion section. All isolates from ARS, which had not been
tested against all of these four antibiotics, were excluded from the analysis. EUCAST clinical
breakpoints for human clinical isolates (S2 Table) were used to interpret the MIC-values from
animal and food isolate data.
Statistical analysis
All MIC values were coded as 0 for susceptible and 1 for resistant. Intermediate results of
human AST were interpreted as susceptible. Once the coding was complete, the relative
Table 1. Comparison of surveillance and monitoring systems for AR in humans and animals in Germany.
Variable ARS ZoMo GERM-Vet
Type of bacteria Human clinical isolates Animal non-clinical isolates (commensal and
food)
Animal clinical isolates
Participation Voluntary Mandatory Voluntary
Population Humans Animal species and food Animal species
AST panel Not harmonized Harmonized Panel Harmonized Panel
14 substances 24 substances
AST methods Broth-Microdilution Broth—Microdilution Broth—Microdilution
(kinetic growth curves)
AST results ‘susceptible’, ‘intermediary’, ‘resistant’ (SIR) or
MIC




EUCAST / CLSI clinical breakpoints EUCAST-ECOFFs CLSI clinical breakpoints for animals
Accreditation All laboratories All laboratories All laboratories
�AST: antimicrobial susceptibility testing.
https://doi.org/10.1371/journal.pone.0244413.t001
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Table 2. Escherichia coli data for different populations collected from Zoonosis-Monitoring, GERM-Vet and ARS from 2014 to 2017.
Isolate type Origin Populations Materials Year
2014 2015 2016 2017
Non-clinical animal
isolates
(27 populations, incl 9
food)
Farm (F) Broilers, F Faeces X
Broilers Conv, F Faeces X
Broilers Org, F Faeces X
Laying hens, F Faeces X
Breeder chickens, F Faeces X
Turkeys, F Faeces X X
Growers <50 kg, F Faeces X
Weaners, F Faeces from waiting area X
Sows, F Faeces of pregnant sows X
Bovine milk, Conv,
F
Bulk tank milk X
Bovine milk, Org,
F
Bulk tank milk X
Bivalves, F Both of shells meat X
Slaughter (S) Broilers, S Pool from ten caecals X X
Turkeys, S Pool from ten caecals X X
Bovines <1year, S Caecals X X
Fattening pigs, S Caecals X X
Retail (R) Venisons, R Fresh Meat X
Shrimps, R Shrimps Meat X
Broiler meat, R Fresh meat with skin X X
Table eggs, R Pool from ten eggshells X
Turkey meat, R Fresh meat with skin X X
Bovine meat, R Fresh meat X
Pork, R Fresh meat X X
Raw sausages, R Fresh meat X
Bivalves, R Both of shells meat X X











Piglets, C Faeces / Intestines/ Swab (Enteritis) X X X X
Growers, C Faeces / Intestines/ Swab (Enteritis) X X X X
Pigs, C Faeces / Intestines/ Swab (Enteritis) X X X X
Sows, C Not specified+ (Mastitis-Metritis-Agalactie—MMA) X X X X
Broilers, C Not specified+ (Septicemia) X X X X
Laying hens, C Not specified+ (Septicemia) X X X X
Turkeys, C Not specified+ (Septicemia) X X X X
Bovines <1year, C Faeces / Intestines/ Swab (Enteritis) X X X X
Cattle, C Faeces / Intestines/ Swab (Enteritis) X X X X
Dairy cows, C Not specified+ (Mastitis) X X X X
Small animals, C Not specified+ (Enteritis/Urinary Tract Infection) X X X X
Clinical human isolates
(3 populations)
Outpatient Humans, A All kind of swabs, blood, punctate, respiratory tract samples, wound samples, urine
and other samples���
X X X X
General Ward Humans, Gw X X X X
Intensive care unit
(ICU)
Humans, ICU X X X X
+Clinical specimens are not specified, only disease information was obtained.
�Data collected from conventional (conv) and organic (org) farms.
��Small animals are cats and dogs.
���All details of materials are listed in S3 Table.
Materials indicate where the specimen that the isolates originated from. Year indicates the different sampling year plan for the non-clinical and clinical animal isolates
and the food isolates.
https://doi.org/10.1371/journal.pone.0244413.t002
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frequency of all 16 possible combinations of resistance to the four antimicrobials was calcu-
lated for each population using the permutation function (24 = 16). Resistance proportions
were calculated using number of tested isolates for each population as denominator. The
relative frequency of the resistance combinations (in %) was determined for each popula-
tion. Building on Jasper et al. [31], we modified hierarchical clustering based on relative fre-
quencies of the resistance combinations for phenotypical AR data. We did not use the
suggested principal component analysis (PCA) for choosing the resistance combinations,
since we had only four antibiotics included. We tested hierarchical clustering using numer-
ous distance measures: single (nearest neighbor), complete (furthest neighbor), and average
linkage (average between nearest and furthest neighbor) and Ward’s method [32]. However,
average linkage with Euclidean distance was selected since it produced the most meaningful
results. A dendrogram and a heatmap were used to visualize the results. In addition to clus-
ter descriptions based on the visualization in a dendogram, we used the elbow method and
silhouette plot [33] for confirming the number of clusters. All analyses were run with R
3.5.1 (Rstudio 1.1.442).
Sensitivity analysis
In an attempt to test the robustness of the result we performed sensitivity analyses. We car-
ried out four analyses, during which one antibiotic at a time was removed from the data.
Thus, the total number of antibiotics in these reduced models was three, resulting in eight
different resistance combinations each. Then, we used our clustering approach to further
analyze the reduced models. Results were compared to clustering using all four antibiotics
(complete model).
Results
Description of included isolates
333,496 E. coli isolates were included from ARS, ZoMo and GERM-Vet between January 2014
and December 2017. 324,304 isolates (97.2%) originated from human populations, 5,743 iso-
lates (1.7%) from healthy food-producing animals and food and 3,449 isolates (1.0%) from dis-
eased animals. Extraction of the data for each surveillance and monitoring system is described
in Fig 1A–1C. Most human isolates (210,005 isolates (64.8%)) originated from urine samples
(S3 Table). Forty-one different populations were defined including 3 human populations, 18
healthy food producing animal populations, 9 food items and 11 diseased animal populations
contributing clinical E. coli isolates (Table 2).
Resistance to the four antimicrobials in isolates from the different
populations
Table 3 demonstrates individual resistance proportions of E. coli from the different human
and animal and food populations to each antibiotic. Overall, resistance proportions were
highest to ampicillin, followed by ciprofloxacin, cefotaxime and gentamicin. They ranged
from 43% to 55% in human clinical isolates, from 1% to 70% in healthy food-producing ani-
mals including wild animals (game) and food and from 16% to 64% in clinical animal iso-
lates. Human clinical isolates from ICU, isolates from several healthy poultry populations
(broilers and turkeys from farm, and slaughterhouse and their meats at retail), and clinical
isolates from bovines <1 year showed the highest resistance proportions to all included
antibiotics.
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Cluster analysis and overall relative frequencies of resistance combinations
in the populations
Three clusters were detected within our dataset (Figs 2 and 3) by visualizing the dendogram
and confirming with the elbow method and silhouette plot (S1 Fig). The heatmap (Fig 2) high-
lights 16 resistance combinations; starting from “susceptible to all” to “resistant to all” (left to
the right). Each column represents the relative frequency of a resistance combination for each
population. Human isolates were mostly exclusively resistant to ampicillin (26–29%), followed
by resistance to ampicillin and ciprofloxacin (6–7%), and resistance to ampicillin, cefotaxime
and ciprofloxacin (4–7%). Isolates from most healthy broiler and turkey populations reported
higher resistance proportions to ampicillin only (46–50%) and to ampicillin and ciprofloxacin
(14–19%) compared to most other populations.
Human isolates of all three populations clustered closely together in the first cluster (Figs 2
and 3). The isolates from the three human populations had similar relative frequencies of resis-
tance combinations. The cluster also included isolates from 14 animal/food populations in two
sub-clusters. Six of these were clinical isolates including subpopulations of all major food pro-
ducing animal species (i.e. cattle, pigs, broilers and turkeys) and companion animals. Clinical
isolates from cattle and piglets and non-clinical isolates from weaned piglets clustered closest
to the human isolates. Two of the healthy poultry populations (broilers from organic farms
and breeder chicken) are included in this cluster. They are separated from other healthy poul-
try populations in cluster three. The second cluster mainly included populations, which had
low relative frequencies of resistance combinations (<25%) for all tested antibiotics and high
proportions of isolates that were susceptible to all tested antimicrobials. The cluster mostly
included food at retail, wild animals, laying hens, and bulk tank milk from dairy herds
Fig 1. Data extraction from three surveillance and monitoring systems for AR. A) ARS system; B) Zoonosis-Monitoring and C) GERM-Vet.
https://doi.org/10.1371/journal.pone.0244413.g001
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Table 3. Individual resistance proportions (%) from different populations against four selected antibiotics; ampicillin (AMP), cefotaxime (CTX), ciprofloxacin
(CIP) and gentamicin (GEN).
Isolate Type Origin Populations Number of tested isolates a
(N)
Resistance Proportions [95% CI] (%)
AMP CTX CIP GEN
Non-clinical animal
isolates
(27 populations, incl 9
food)
Farm (F) Weaners, F 250 50.8 [44.4; 57.2] 4.4 [2.2; 7.7] 4.0 [1.9; 7.2] 2.4 [0.9; 5.2]
Laying hens, F 347 13.3 [9.9; 17.3] 3.2 [1.6; 5.6] 2.0 [0.8; 4.1] 0.9 [0.2; 2.5]
Broilers, F 184 72.3 [65.2; 78.6] 2.2 [0.6; 5.5] 22.8 [17.0; 29.6] 1.1 [0.1; 3.9]
Broilers Conv, F 299 70.2 [64.7; 75.4] 1.0 [0.2; 2.9] 18.7 [14.5; 23.6] 1.0 [0.2; 2.9]
Broilers Org, F 31 22.6 [9.6; 41.1] 0 [0; 11.2] 9.7 [2.0; 25.8] 3.2 [0; 16.7]
Turkeys, F 346 62.4 [57.1; 67.6] 0.6 [0.1; 2.1] 23.1 [18.8; 28.0] 8.4 [5.7; 11.8]
Growers <50 kg, F 210 34.8 [28.3; 41.6] 1 [0.1; 3.4] 2.4 [0.8; 5.5] 1.9 [0.5; 4.8]
Bovine milk, Conv, F 122 5.7 [2.3; 11.5] 0 [0; 3] 0.8 [0; 4.5] 0 [0; 3]
Bovine milk, Org, F 74 1.4 [0; 7.3] 0 [0; 5.0] 0 [0; 5.0] 0 [0; 5.0]
Breeder chickens, F 56 25.0 [14.4; 38.4] 0 [0; 6.4] 7.1 [2.0; 17.3] 5.4 [1.1; 14.9]
Sows, F 24 26.5 [21.3; 32.1] 1.5 [0.4; 3.7] 1.8 [0.6; 4.2] 2.2 [0.8; 4.7]
Bivalves, F 42 9.5 [2.7; 22.6] 0 [0; 8.4] 0 [0; 8.4] 2.4 [0; 12.6]
Slaughter (S) Broilers, S 404 57.2 [52.2; 62.1] 0.3 [0.1; 1.4] 10.6 [7.8; 14.1] 6.4 [4.3; 9.3]
Bovines <1year, S 433 34.2 [29.7; 38.9] 1.8 [0.8; 3.6] 2.8 [1.4; 4.8] 0.9 [0.3; 2.3]
Turkeys, S 372 63.7 [58.6; 68.6] 1.6 [0.6; 3.5] 19.6 [15.7; 24.0] 8.1 [5.5; 11.3]
Fattening pigs, S 439 31.2 [26.9; 35.8] 2.5 [1.3; 4.4] 2.1 [0.9; 3.9] 0.5 [0; 1.6]
Retail (R) Venisons, R 150 2 [0.4; 5.7] 0 [0; 2.4] 0 [0; 2.4] 0 [0; 2.4]
Shrimps, R 20 20 [5.7; 43.7] 10 [1.2; 31.7] 10 [1.2; 31.7] 5 [0; 24.9]
Broiler meat, R 363 54.8 [49.5; 60.0] 4.4 [2.5; 7.1] 19.0 [15.1; 23.4] 3.0 [1.5; 5.4]
Table eggs, R 90 11.1 [5.5; 19.5] 0 [0; 4] 1.1 [0; 6.0] 1.1 [0; 6.0]
Turkey meat, R 356 67.4 [62.3; 72.3] 3.4 [1.8; 5.8] 21.3 [17.2; 26.0] 8.7 [6.0; 12.1]
Bovine meat, R 115 11.3 [6.2; 18.6] 2.6 [0.5; 7.4] 0.9 [0; 4.8] 0 [0; 3.2]
Pork, R 155 25.2 [18.5; 32.8] 2.6 [0.7; 6.5] 0 [0; 2.3] 0.6 [0; 3.5]
Raw sausage, R 69 20.3 [11.6; 31.7] 1.5 [0; 7.8] 7.3 [2.4; 16.1] 1.5 [0; 7.8]
Bivalves, R 58 8.6 [2.9; 19.0] 0 [0; 6.1] 3.5 [0.4; 11.9] 0 [0; 6.1]
Wild/Game (W) Roe deer hunted, W 269 1.5 [0.4; 3.8] 0.4 [0.1; 2.1] 0 [0; 1.4] 0 [0; 1.4]
Wild boar hunted,
W






Piglets, C 417 61.4 [56.5; 66.1] 6.5 [4.3; 9.3] 8.9 [6.3; 12.0] 7.2 [5.0; 10.1]
Laying hens, C 557 15.6 [12.7; 18.9] 0.9 [0.3; 2.1] 2.3 [1.3; 4.0] 1.8 [0.9; 3.3]
Bovines <1year, C 534 71.4 [67.3; 75.2] 30.5 [26.6;
34.6]
36.0 [31.9; 40.2] 29.4 [25.6;
33.5]
Small animals, C 312 34.3 [29.0; 39.9] 10.3 [7.1; 14.2] 16.4 [12.4; 20.9] 5.8 [3.5; 9.0]
Growers, C 129 63.6 [54.6; 71.9] 7.0 [3.2; 1.3] 2.3 [0.5; 6.6] 4.7 [1.7; 9.8]
Broilers, C 232 35.4 [29.2; 41.9] 3.9 [1.8; 7.2] 5.2 [2.7; 8.9] 4.7 [2.4; 8.3]
Dairy cows, C 378 18.5 [14.7; 22.8] 7.1 [4.8; 10.2] 6.1 [3.9; 9.0] 3.4 [1.8; 5.8]
Turkeys, C 327 40.4 [35.0; 45.9] 0.3 [0; 1.7] 5.5 [3.3; 8.6] 4.3 [2.4; 7.1]
Cattle, C 193 47.2 [39.9; 54.5] 14.5 [9.9; 20.3] 22.8 [17.1; 29.4] 15.0 [10.3;
20.9]
Pigs, C 346 49.7 [44.3; 55.1] 5.2 [3.1; 8.1] 6.1 [3.8; 9.1] 4.6 [2.7; 7.4]
Sows, C 24 29.2 [12.6; 51.1] 0 [0; 14.2] 4.2 [0.1; 21.1] 4.2 [0.1; 21.1]
Clinical human isolates
(3 populations)
Outpatient (A) Humans, A 96,455 42.7 [42.4; 42.9] 7.3 [7.2; 7.4] 15.2 [15.0; 15.3] 4.8 [4.7; 4.9]
General Ward (Gw) Humans, Gw 197,521 49.2 [49.2; 49.4] 11.5 [11.3;
11.6]
19.5 [19.4; 19.6] 5.8 [5.7; 5.9]
Intensive Care Unit
(ICU)
Humans, ICU 30,328 54.9 [54.4; 55.5] 15.8 [15.4;
16.1]
22.0 [21.5; 22.4] 6.9 [6.6; 7.2]
aNumber of tested isolates is the sum of all sensible (0) and all resistant (1) isolates.
The denominator was number of isolates from the respective population tested against each antibiotic from 2014 to 2017.
https://doi.org/10.1371/journal.pone.0244413.t003
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including from organic dairy production. The third cluster contained mostly healthy poultry
(7 out of the 10 populations). Besides healthy poultry the cluster contained isolates from poul-
try meat, clinical isolates from pigs and, slightly separated, clinical isolates from young cattle.
Sensitivity analysis
Elimination of individual antibiotics from the model led to changes in the clusters (S2A–S2D
Fig). In each elimination process, human inpatient isolates (ICU and general ward) always
Fig 2. Heatmap describes different relative frequencies of resistance combinations for each population. From grey
to red it shows the lowest to highest relative frequencies of resistance combinations. The x-axis explains the resistant
combinations; from all susceptible (left) to all resistant (right). Antibiotics are described with ‘0’ as ‘susceptible’ and ‘1’
‘resistant’. The order is GEN (gentamicin), CIP (ciprofloxacin), CTX (cefotaxime) and AMP (ampicillin). The y-axis
denotes each population together with their clusters.
https://doi.org/10.1371/journal.pone.0244413.g002
Fig 3. Cluster dendogram of different animal and human populations based on the relative frequency of
resistance combinations to ampicillin, cefotaxime, ciprofloxacin and gentamicin. The x-axis describes the averaged
similarities between the populations and between clusters. The y-axis shows each population and different clusters.
https://doi.org/10.1371/journal.pone.0244413.g003
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clustered together. Likewise, the sub-clustering of isolates from some of poultry isolates (broil-
ers from conventional farms and all isolates from turkeys (farm, slaughterhouse and meat));
wild animals (roe deer hunted, wild boar hunted and venisons); bovine milk from organic and
conventional farms remained in same sub-cluster.
After eliminating ampicillin data, most healthy poultry isolates (except broilers from
organic farms, breeder chickens and laying hens from farms and broilers from the slaughter-
house) clustered together with human isolates. Human isolates from outpatient care clustered
closely with clinical isolates from small animals instead of with clinical isolates from cattle but
remained the next neighbor to the inpatient isolates (S2A Fig).
After eliminating cefotaxime data, human isolates from ICU and general ward likewise
clustered with most of healthy poultry populations, again with the exception of broilers from
organic farms, breeder chickens and laying hens from farms. In this model, we found that
human isolates from ICU and general ward cluster closely with broiler meat at retail. Without
considering cefotaxime, human isolates from outpatient care clustered separately from those
of inpatients indicating that resistance to cefotaxime might be important for their close associ-
ation in the full model. As in the full model, they clustered with clinical isolates from cattle.
Eliminating ciprofloxacin data, human isolates from ICU and general ward clustered with
isolates from weaners, clinical isolates from piglets and broiler meat at retail. Human isolates
from outpatient care stayed in one cluster with human isolates from ICU and general ward but
not as their closest neighbor. They clustered together with clinical isolates from turkeys. All
healthy poultry populations, again except broilers from organic farms, breeder chickens and
laying hens from farms, clustered separately.
By eliminating gentamicin, the model outcome did not differ substantially from the com-
plete model.
Discussion
Cluster analysis provided information on similarities of E. coli isolates from humans and dif-
ferent animal populations based on their resistance combinations.
Human isolates from ICU and general ward always clustered together in cluster 1. Isolates
from outpatient care were the next closest link in the full model and in two of the four reduced
models. This finding supports the hypotheses that most ICU isolates are related to isolates
from other parts of the hospital and from outpatients [34]. Studies on transmission within
health-care-network and patient transfers have also supported this idea [35–37]. The slightly
larger distance of the outpatient populations in comparison to the inpatient populations (gen-
eral ward and ICU) might be explained by the specific situation in hospitals, with dominant
hospital strains that differs from the outpatient setting [8]. Moreover, in the full model, isolates
from the three human clinical populations clustered with clinical isolates from most (6/11) ani-
mal populations; i.e. cattle, piglets, sows, turkeys, broilers and small animals. The reason for
these similarities between clinical isolates from human and different animal populations
remains unclear as transmission of clinical isolates from animals to humans by contact or food
is unlikely.
Isolates from most pig populations clustered together with the human clinical isolates
(Cluster 1). This included clinical and non-clinical isolates from pigs. Prevalence of AR in pigs
is associated with overall country-specific antimicrobial usage in livestock [38] Penicillins and
tetracyclines are among the most frequently used antibiotics in pigs in Germany [39, 40]. This
might explain the high proportions of resistance only to ampicillin in our study. Tetracyclines
had to be excluded from this study as they were only tested in few medical laboratories. Their
inclusion would have been associated with a substantial loss of data on the medical side as only
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isolates tested against all study antimicrobials could be included. The highest proportion of
ampicillin-resistance in this cluster was found in weaners (fattening piglets, up to 30kg body
weight) from farms (42%) (Fig 2). Higher single ampicillin resistance in weaners in compari-
son to other pig populations may have been caused by a higher treatment frequency with peni-
cillins in piglets around and weaning time to address streptococcal infections in comparison to
older fattening pigs [39, 40]. Two groups of clinical isolates from pigs and growers clustered
separately from the other pig populations in cluster 3. This separation was associated with
higher proportions of resistance only to ampicillin in these two populations and lower propor-
tions of susceptibility to all four studied antimicrobials than in the other pig populations.
As for healthy pigs, the transmission of bacteria from pigs to humans could be explained
via food consumption. Pork is occasionally consumed raw in Germany. It is in line with our
study findings, which found isolates from pork and human clinical isolates in the same cluster.
However, the clinical isolates are not likely to be transmitted via food as food is harvested from
healthy animals. Another possible explanation is the similar antimicrobial usage (AMU)-pat-
tern between humans and pigs for the antimicrobials included which may create similar resis-
tance patterns, as penicillins are also frequently used in humans. In that case, the clustering
would have been caused by parallel developments rather than by transmission of isolates. This
explanation could also embrace the clinical isolates.
Our study indicates separate clusters for clinical human isolates (cluster 1) and isolates
from most healthy broilers (except broilers from organic farms), and turkey populations and
their meat (cluster 3) and for laying hens (cluster 2). It has been reported that extended-spec-
trum cephalosporin-resistant E. coli from healthy poultry are unlikely to be the causative
agents of human UTI [41]. Another study revealed low similarities of ESBL/AmpC genes
between broilers and the general human population with the exception of the broiler farming
communities [8] In line with that, our study indicates a lack of similarities in resistance to the
four antimicrobials of E. coli from human and healthy broiler and turkey populations and lay-
ing hens.
In the third cluster, healthy broilers and turkeys along with their meats clustered together.
AR in non-clinical E. coli isolates from broilers is associated with antimicrobial use in poultry
production. Resistance proportions in E. coli to penicillins and fluoroquinolones are reported
to be 40% higher in countries which have allowed the use of these two antibiotics in poultry
than countries which have not [42]. In Germany, ampicillin and enrofloxacin, a fluoroquino-
lone with a similar chemical structure as ciprofloxacin, are authorized antibiotics for the treat-
ment of poultry [43]. The total treatment frequencies of penicillins and fluoroquinolones in
fattening turkeys and chickens are higher compared to pigs and cattle [39]. This might be the
reason for higher individual resistance proportions against ampicillin and ciprofloxacin and
the higher relative frequencies of the combinations of resistance to both substances compared
to other populations [43].
Three non-clinical poultry populations: broilers from organic farms, laying hens and
breeder chickens, and two clinical poultry populations: broilers and turkeys were not included
in this third cluster (Fig 3). Broilers from organic farms, laying hens and breeder chickens
have lower individual resistance proportions against the studied antimicrobials compared to
the other healthy poultry populations. This is in line with earlier work on lower resistance pro-
portions in broilers and turkeys from organic farms [44–46]. Lower antibiotic resistance rates
might be caused by lower antibiotic usage in organic farming. EU legislation governing
organic farming (Reg. (EC) No. 834/2007) foresees the use of antibiotics solely for diseased
animals, if phytotherapeutic drugs, homeopathy and other products are not working. This
includes the restriction on number of treatments and longer duration of withdrawal periods
[47, 48]. This may contribute to a lower use of antibiotics in organic broiler farming compared
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to conventional farming. However, valid specific use data from organic poultry farms are not
available for Germany.
For breeder chickens and laying hens, low relative frequencies of resistance combinations
were detected with resistance in laying hens even lower than in breeder chickens. Low single
resistant proportions to the four chosen antibiotics in these two populations have been previ-
ously reported [49, 50]. Laying hens and breeder chickens received less antibiotic treatment
than broilers, with the lowest antibiotic treatment in laying hens [51]. We, therefore, assume
that the low relative frequencies of resistance combinations are associated with less antibiotic
treatments received in laying hens and breeder chickens compared to broilers. Breeder chick-
ens, i.e. parents and grand-parent flocks of production chicken, and laying hens live longer
than broilers that only have a lifespan of approximately 4–6 weeks. It seems reasonable that the
microbiome of breeder chickens and laying hens has matured [52, 53]. These microbiomes
may be more competitive and resilient than those in young broilers contributing to less disease
and therefore fewer treatments. Moreover, the housing conditions of breeder chickens are
strictly controlled [54]. A controlled housing management might reduce the prevalence of
pathogens and their transmission, which also results in fewer antibiotic treatments.
Clinical isolates from broilers and turkeys have lower resistance proportions to ampicillin
compared to non-clinical isolates from broilers and turkeys (Fig 2). This applies also for the
combined resistance proportions to ampicillin and ciprofloxacin. The reasons for these lower
resistance rates in clinical isolates are however unclear and should be further investigated.
Isolates from wild animals, i.e. wild boars, wild roe deer and venison, clustered closely
together with bulk tank milk both from conventional and organic farms. Isolates from these
five populations showed the lowest individual resistance proportions and relative frequency of
resistance combinations of all populations. Wild animals receive no antibiotic treatment, and
therefore are not directly exposed to antimicrobials. However, wild animals were reported to
carry AR commensal E. coli (non-clinical E. coli isolates) and play a role as sentinels of envi-
ronmental transmission of AR [55, 56]. The presence of AR in wild animals has been associ-
ated to geographical distance to AR sources, such as wastes of antibiotic treated animals or
humans [55], and also to human population density [57].
E. coli from bulk tank milk from both conventional and organic farms had low resistance
rates and relative frequencies of resistance combinations. Low presence of AR in commensal
E. coli (non-clinical E. coli isolates) from bulk tank milk has been previously reported [58, 59].
Low use of antibiotics in dairy cattle [51, 60] might result in low AR in the bacteria in milk.
However, as E. coli is not part of the healthy milk microbiota and milk from E. coli mastitis is
as a rule discarded, the most common source of E. coli in bulk tank milk is environmental, i.e.
fecal contamination, mostly originating from the dairy herd [61] Improper milking-system
hygiene also plays a role in milk contamination with coliform bacteria from the environment
[62], but probably has no impact on their resistance patterns.
Clinical isolates from bovines <1 year had the highest individual proportions of AR for all
four antibiotics as well as the highest relative frequency of the resistance combinations
(Table 3 and Fig 2). This resulted in higher proportions of resistance combinations in compar-
ison to other populations. Many of the isolates originated from young calves with enteritis.
Use of waste milk may have contributed to the high resistance rates [63–65], given that penicil-
lins and cephalosporins are frequently used in the treatment of mastitis of dairy cows [66, 67].
Waste milk is likely to contain residues of antimicrobials especially after intramammary treat-
ment of dairy cows. This however cannot explain the comparatively high resistance rates to
gentamicin and ciprofloxacin, as these substances are not frequently used in intramammary
treatment. Further research into the dynamics of AR in calves is needed to improve the under-
standing of our study results.
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Clinical animal isolates frequently clustered separately from their healthy animal counter-
parts. Our animal samples originated from two different independent datasets. There is no
information whether they originated from the same farms. However, given the large number of
farms and the limited number of isolates a large overlap of the source is unlikely. The separation
might be caused by differences in selection pressure between the clinical and non-clinical iso-
lates, although they originated from the same animal species and type of population. Non-clini-
cal food-producing animal incl. food isolates were randomly sampled from each federal state in
Germany. Clinical food-producing and companion animal isolates might be particular isolates
from ill animals that form a specific subpopulation of E. coli strains. The GERM-Vet study pro-
tocol states that the animals of origin should not have been treated with antibiotics within a
month prior to sampling. However, it seems possible that these pathogenic isolates had prior
specific antibiotic selection pressure in the animal population before the sampling time. An ear-
lier study found the same tetracycline and aminoglycosides resistance genes in commensal
(non-clinical isolates) and clinical E. coli [68]. Further research into the two different bacterial
populations is necessary to better understand the reasons for the differences in AR.
With the sensitivity analysis we aimed to look into consistency of clusters built from the
complete model (Fig 3). Some populations, i.e. human isolates from inpatient care (ICU and
general ward) and isolates from wild animals and bovine milk from organic farm; remained in
the same sub clusters consistently. This underlines their very close similarity with respect to
resistance to the four antimicrobials and a distance to isolates from the other populations.
Removal of individual antimicrobials from the analysis also resulted in changes in cluster
distributions compared to the complete model. The removal of one of the three antimicrobials
—ampicillin, cefotaxime and ciprofloxacin—at a time made human clinical isolates from out-
patient care change their position and nearest neighbors. This indicates a certain distance to
the inpatient isolates. On the other hand, the change in the closest neighbor depending on the
antimicrobial that was removed indicates that there was no clear relation to any individual
other population. Removal of one antibiotic influenced the relative frequency proportions of
resistance combinations. Resistance rates to ampicillin and ciprofloxacin were high in our
study populations. Therefore, the removal of these two antibiotics substantially influenced the
cluster order. In contrast, removal of gentamicin did not influence the clusters much. While a
full analysis of these findings is outside the scope of this paper, we propose further analyses
including additional antibiotics in order to understand the importance of different antibiotic
usages in human and animal sectors.
There are a number of limitations to this study that must be acknowledged. Due to differ-
ences in the antimicrobials tested in the three systems, we had to choose four common antibi-
otics that overlapped between the three systems and for which sufficient data were available in
ARS. Inclusion of further antimicrobials (e.g. tetracycline), would have reduced the number of
available isolates in ARS substantially and would have excluded data from several laboratories,
as those did not test E. coli for tetracycline resistance routinely. In ZoMo trimethoprim and
sulfonamides are tested as individual substances, while in GERM-Vet and human clinical iso-
lates frequently a combination of a sulfonamide and trimethoprim is tested. Colistin and car-
bapenems have also not been taken into consideration. Colistin is used as a last resort
antibiotic in the human sector. However, for methodological reasons phenotypical resistance
data to colistin generated with automated methods are not considered reliable. Regarding car-
bapenems, different substances were used for animal clinical (imipenem) and non-clinical iso-
lates (meropenem) and therefore data were not considered comparable. Moreover, resistance
to carbapenem is extremely rare in animals [69] and also rare in humans in Germany [70].
We used SIR results based on clinical evaluation criteria for humans from EUCAST, as we
could re-evaluate the quantitative data from the animal monitoring systems based on these
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breakpoints. As for the human data, either no quantitative data were available or the tested
range was so narrow that a re-evaluation according to ECOFFs was not possible.
This study highlights substantial differences between the three monitoring and surveillance
systems (Table 1). Differences in data collection (surveillance versus monitoring), participa-
tion system (mandatory versus voluntarily), observed populations (humans versus different
animal populations), AST (panel, methods and results) and evaluation criteria (clinical break-
points and epidemiological cut-off values) should be carefully considered for comparative
analysis. For the purpose of comparing resistance proportions, it would be desirable that the
One Health community strives towards harmonized evaluation criteria for each antimicrobial
in isolates from humans, food-producing animals and food. Alternatively, quantitative data,
such as MIC values, need to be collected for allowing the interpretation using different stan-
dards based on any required analysis. Rational criteria should be shaped based on various pur-
poses, such as for treatment decisions and comparative analysis of different resistant
proportions across different sectors. Joint harmonized MIC value ranges for comparative anal-
yses of human and animal data would better fit for the analysis.
Since routine standardized diagnostics differ between human and animal sectors, it needs
to be investigated whether the different laboratory methods yield comparable results. Routine
methods are always a compromise between scientific accuracy and economic needs. Increasing
costs might discourage widespread use of costly and laborious AST methods in routine labora-
tories, an aspect that is less relevant in monitoring programs with limited numbers of isolates.
To the best of our knowledge, this is the first study that systematically compares the routine
laboratory surveillance and monitoring systems for AR in humans with different animal popu-
lations and food of animal origin in Germany using cluster analysis. Within the limitations
noted above, our results indicate that patterns of resistance combinations are able to provide
insights in similarities and discrepancies between isolates from different human and animal
populations. Given the current situation on surveillance and monitoring for AR in Germany,
we considered it the best approach to compare the national data on AR in E. coli from humans,
different animal populations and food based on their phenotypical resistance combinations.
Regional analyses within the country and across countries might provide valuable additional
insights. However, further stratification of the data would lead to very small strata for some of
the populations. This would likely lead to exclusion of several populations from the analysis. In
this study, we would like to avoid this type of exclusion to be able to validly compare as many
populations as possible. Although phenotypic datasets are able to promote the study on resis-
tance combinations, the findings of this study suggest a number of directions, which future
studies on molecular level on AR might profitably take. Integration of whole genome sequenc-
ing (WGS) into surveillance might help further research into resistance genes similarities. Ini-
tiatives on implementation of WGS in AR monitoring system for animals have been already
started [71, 72]. As genomic information provides better insights into resistance mechanisms,
mobile genetic elements, chromosomal mutations and intrinsic resistance, its inclusion in the
comparative analysis should be further promoted.
Conclusion
This study provides insights into possible analyses of AR phenotypical data from routine surveil-
lance and monitoring in Germany. Despite differences in collected variables within the different
surveillance and monitoring systems, cluster analysis has shown similarities and discrepancies
between resistance patterns in isolates from humans and different animal populations for four
frequently tested antibiotics. Using our datasets and analytical approach, we are not able to sub-
stantiate any transmission between humans, animals and foods. However, if the observed
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populations clustered separately, it is unlikely that a substantial amount of transmission between
the populations has occurred. Initiatives built based on these results might promote successful
‘One Health’ improvements across human and different animal populations in Germany.
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gischen Erzeugnissen und zur Aufhebung der Verordnung (EWG) Nr. 2092/91, ABl. Nr. L 189 vom
20.07.2007, S. 1. 2007.
49. Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, Bundesinsitut für Risikobewertung. Ber-
ichte zur Lebensmittelsicherheit 2011, Zoonosen-Monitoring Berlin: Bundesinstitut für Risikobewertung;
2013.
50. European Food Safety Authority, European Centre for Disease Prevention Control. The European
Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Out-
breaks in 2011. EFSA Journal. 2013; 11(4):3129.
51. Autoriteit Diergeneesmiddelen (SDA). Usage of Antibiotics in Agricultural Livestock in the Netherlands
in 2018: Trends and benchmarking of livestock farms and veterinarians. Utrecht: Autoriteit Diergenees-
middelen; 2019.
PLOS ONE Cluster analysis of Escherichia coli from different human and animal populations in Germany
PLOS ONE | https://doi.org/10.1371/journal.pone.0244413 January 20, 2021 18 / 19
52. Shang Y, Kumar S, Oakley B, Kim WK. Chicken Gut Microbiota: Importance and Detection Technology.
Front Vet Sci. 2018; 5:254. https://doi.org/10.3389/fvets.2018.00254 PMID: 30406117
53. Lee S, La T-M, Lee H-J, Choi I-S, Song C-S, Park S-Y, et al. Characterization of microbial communities
in the chicken oviduct and the origin of chicken embryo gut microbiota. Scientific Reports. 2019; 9
(1):6838. https://doi.org/10.1038/s41598-019-43280-w PMID: 31048728
54. EFSA Panel on Animal Health Welfare. Scientific Opinion on welfare aspects of the management and
housing of the grand-parent and parent stocks raised and kept for breeding purposes. EFSA Journal.
2010; 8(7):1667.
55. Swift BMC, Bennett M, Waller K, Dodd C, Murray A, Gomes RL, et al. Anthropogenic environmental
drivers of antimicrobial resistance in wildlife. Sci Total Environ. 2019; 649:12–20. https://doi.org/10.
1016/j.scitotenv.2018.08.180 PMID: 30170212
56. Arnold KE, Williams NJ, Bennett M. ’Disperse abroad in the land’: the role of wildlife in the dissemination of
antimicrobial resistance. Biol Lett. 2016; 12(8). https://doi.org/10.1098/rsbl.2016.0137 PMID: 27531155
57. Mo SS, Urdahl AM, Madslien K, Sunde M, Nesse LL, Slettemeas JS, et al. What does the fox say? Mon-
itoring antimicrobial resistance in the environment using wild red foxes as an indicator. PLoS One.
2018; 13(5):e0198019. https://doi.org/10.1371/journal.pone.0198019 PMID: 29799852
58. Dell’Orco F, Gusmara C, Loiacono M, Gugliotta T, Albonico F, Mortarino M, et al. Evaluation of virulence
factors profiles and antimicrobials resistance of Escherichia coli isolated from bulk tank milk and raw
milk filters. Res Vet Sci. 2019; 123:77–83. https://doi.org/10.1016/j.rvsc.2018.12.011 PMID: 30594031
59. Berge AC, Champagne SC, Finger RM, Sischo WM. The use of bulk tank milk samples to monitor
trends in antimicrobial resistance on dairy farms. Foodborne Pathog Dis. 2007; 4(4):397–407. https://
doi.org/10.1089/fpd.2007.0009 PMID: 18041950
60. Berry EA, Hillerton JE. The effect of selective dry cow treatment on new intramammary infections. J
Dairy Sci. 2002; 85(1):112–21. https://doi.org/10.3168/jds.S0022-0302(02)74059-9 PMID: 11860103
61. Martin NH, Trmčić A, Hsieh T-H, Boor KJ, Wiedmann M. The Evolving Role of Coliforms As Indicators
of Unhygienic Processing Conditions in Dairy Foods. Frontiers in microbiology. 2016; 7:1549-. https://
doi.org/10.3389/fmicb.2016.01549 PMID: 27746769
62. Pantoja JCF, Reinemann DJ, Ruegg PL. Factors associated with coliform count in unpasteurized bulk
milk. Journal of Dairy Science. 2011; 94(6):2680–91. https://doi.org/10.3168/jds.2010-3721 PMID:
21605737
63. EFSA Panel on Biological Hazards, Ricci A, Allende A, Bolton D, Chemaly M, Davies R, et al. Risk for
the development of Antimicrobial Resistance (AMR) due to feeding of calves with milk containing resi-
dues of antibiotics. EFSA Journal. 2017; 15(1):e04665. https://doi.org/10.2903/j.efsa.2017.4665 PMID:
32704309
64. Aust V, Knappstein K, Kunz HJ, Kaspar H, Wallmann J, Kaske M. Feeding untreated and pasteurized
waste milk and bulk milk to calves: effects on calf performance, health status and antibiotic resistance
of faecal bacteria. J Anim Physiol Anim Nutr (Berl). 2013; 97(6):1091–103.
65. de Verdier K, Nyman A, Greko C, Bengtsson B. Antimicrobial resistance and virulence factors in
Escherichia coli from Swedish dairy calves. Acta Vet Scand. 2012; 54:2. https://doi.org/10.1186/1751-
0147-54-2 PMID: 22280887
66. Merle R, Mollenhauer Y, Hajek P, Robanus M, Hegger-Gravenhorst C, Honscha W, et al. Verbrauchs-
mengenerfassung von Antibiotika beim Rind in landwirtschaftlichen Betrieben. Berliner und Münchener
tierärztliche Wochenschrift. 2013; 126(7–8):318–25. PMID: 23901587
67. Krömker V, Leimbach S. Mastitis treatment—Reduction in antibiotic usage in dairy cows. Reproduction
in Domestic Animals. 2017; 52(S3):21–9. https://doi.org/10.1111/rda.13032 PMID: 28815847
68. Szmolka A, Nagy B. Multidrug resistant commensal Escherichia coli in animals and its impact for public
health. Front Microbiol. 2013; 4:258. https://doi.org/10.3389/fmicb.2013.00258 PMID: 24027562
69. Irrgang A, Tenhagen B-A, Pauly N, Schmoger S, Kaesbohrer A, Hammerl JA. Characterization of VIM-
1-Producing E. coli Isolated From a German Fattening Pig Farm by an Improved Isolation Procedure.
Frontiers in Microbiology. 2019; 10(2256). https://doi.org/10.3389/fmicb.2019.02256 PMID: 31632372
70. European Centre for Disease Prevention Control. Surveillance of antimicrobial resistance in Europe
2018. Stockholm: European Centre for Disease Prevention Control; 2019.
71. European Food Safety Authority, Aerts M, Battisti A, Hendriksen R, Kempf I, Teale C, et al. Technical
specifications on harmonised monitoring of antimicrobial resistance in zoonotic and indicator bacteria
from food-producing animals and food. EFSA Journal. 2019; 17(6):e05709. https://doi.org/10.2903/j.
efsa.2019.5709 PMID: 32626332
72. Brown E, Dessai U, McGarry S, Gerner-Smidt P. Use of Whole-Genome Sequencing for Food Safety
and Public Health in the United States. Foodborne pathogens and disease. 2019; 16(7):441–50. https://
doi.org/10.1089/fpd.2019.2662 PMID: 31194586
PLOS ONE Cluster analysis of Escherichia coli from different human and animal populations in Germany
PLOS ONE | https://doi.org/10.1371/journal.pone.0244413 January 20, 2021 19 / 19
